HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Clinical activity in ESR1 mutant versus wild type
Hamilton contrasts activity of oral CERDs/PROTACs in ESR1‑mutant and wild‑type disease and interpretation of trial statistics.
Play episode from 06:59
Transcript
